Search Results for pharma (Corporate Dealmaker)

Advanced Search

Sort ByDate Relevance	Search InCorporate Dealmaker The entire Deal Blogs Network

16 result(s) displayed (1 - 16 of 16):

Prescription for growth: CVS Caremark acquires Longs Drugs (from Corporate Dealmaker)

As part of its growth strategy CVS Caremark Corp. has acquired Longs Drug Stores for $2.9 billion. The acquisition will add 521 more drugstores in California, Hawaii, Nevada and Arizona to make the grand total of CVS Caremark's drugstores 6,800 in 41 states. The deal will also add to its...

Posted on August 12, 2008 5:56 PM

Schering-Plough buys out JV partners in China (from Corporate Dealmaker)

To expand its presence in China, Schering-Plough Corp. bought out two local joint venture partners. Schering-Plough started the ventures with Shanghai Pharmaceutical Industry Co. and Shanghai Pharmaceutical Group Co. in 1994. Both companies manufacture allergy and skincare products. Schering will combine the two companies into a subsidiary named Shanghai Schering-Plough...

Posted on August 12, 2008 5:19 PM

Elan: Spin it and spin it fast (from Corporate Dealmaker)

Elan Corp. plc isn't wasting any time spinning off its drug delivery unit, Elan Drug Technologies. The company has already received first bids for the unit that it announced at the end of July it may spin off. Elan sunk, apparently, due to the unit's agreement with Biogen Idec Inc....

Posted on August 12, 2008 11:24 AM

Biotech, pharma dealmakers really like i-bankers, survey says (from Corporate Dealmaker)

The corporate dealmakers we talk to tend to have short, well-defined lists of things they like to use investment bankers for. See, for example, our post on the fact that Oracle Corp. accomplished its big, hostile takeover of BEA Systems Inc. without i-bankers, and also this very funny column by...

Posted on July 3, 2008 11:22 AM

Pfizer's big push in oncology (from Corporate Dealmaker)

With the medical world gearing up for a huge oncology conference in Chicago this weekend, Pfizer Inc. announced it had lured away Eli Lilly & Co.'s oncology business chief Garry Nicholson to run its own similar unit, which the drug giant formed earlier this year.With a string of high-profile duds...

Posted on May 15, 2008 2:25 PM

Pharma CFOs should be more strategic, survey says (from Corporate Dealmaker)

Ernst & Young has released a survey of 95 drug industry executives that shows heightened expectations for chief financial officers. As the industry grapples with slowing sales, tightening regulations, more aggressive generic competition, rapid globalization and a mountain of expiring patents, CFOs are expected to look beyond bean-counting and become...

Posted on March 28, 2008 9:01 AM

In the lead: Pfizer and Sun World (from Corporate Dealmaker)

Ringo's tall order at PfizerNew Pfizer Inc. dealmaker William Ringo has quite a job ahead. The longtime drug executive -- he spent nearly three decades at Eli Lilly and Co., then was CEO at biotech Abgenix Inc., which he helped sell to Amgen Inc. for $2 billion, and most recently...

Posted on March 12, 2008 1:38 PM

Getting more out of teams (from Corporate Dealmaker)

A look at the art and (maybe) science of managing the cast of characters needed to make deals successful.

Posted on August 15, 2007 7:10 PM

Tech Transfer: From bioscience to defense (from Corporate Dealmaker)

U.S. Genomics hopes to adapt its analyzer technology to detect bioterror threats, like the anthrax sent through U.S. mail.

Posted on August 15, 2006 11:31 AM

Trend Tracker: March-April 2006 (from Corporate Dealmaker)

Google's pure VC play, new guidelines for DNA tech transfer, joint ventures in Russia, and heated competition in outsourcing.

Posted on April 15, 2006 4:03 PM

A kick-start for Boots (from Corporate Dealmaker)

If approved by the High Court in London and Alliance stockholders, Alliance Boots will be Europe's largest retail pharmacy owner.

Posted on April 15, 2006 3:44 PM

Alliance Rx (from Corporate Dealmaker)

Baxter's Norbert Riedel brings a keen eye for cultural nuance to the competition for partners.

Posted on June 15, 2005 6:26 PM

Shire's drug seeker (from Corporate Dealmaker)

Shire Pharmaceuticals Group plc is Britain's third-largest pharmaceuticals company, but it doesn't have a team of brainy scientists hunched over test tubes trying to come up with the world's next big blockbuster drug.

Posted on April 15, 2005 2:05 PM

Jacquesson rises at Sanofi-Aventis (from Corporate Dealmaker)

One of the year's major mergers was officially consummated in August, and the first big development was the naming of a new head of business development. Olivier Jacquesson now has that job at Sanofi-Aventis, serving on the management committee and reporting to CEO Jean-François Dehecq. The manner of Jacquesson's...

Posted on December 15, 2004 10:13 AM

Lilly's prescription for growth (from Corporate Dealmaker)

Eli Lilly and Co. spent $2.4 billion on life-science R&D last year, exploring everything from antisense technology to synthetic exendin-4. But the biggest experiment under way at the company isn't taking place in a lab or a clinic. And the results of that experiment - highly promising so far...

Posted on August 15, 2004 5:45 PM

So how do you manage an alliance? (from Corporate Dealmaker)

Patricia Martin has been an energetic advocate, both inside and outside Eli Lilly and Co., for a simple idea. "There's life after the deal," she says. "And it's worth paying attention to." That in a nutshell is the mission of Lilly's Office of Alliance Management, which monitors, supports and helps...

Posted on August 15, 2004 2:44 PM